Cargando…
Developing and evaluating stereotactic lung RT trials: what we should know about the influence of inhomogeneity corrections on dose
PURPOSE: To investigate the influence of inhomogeneity corrections on stereotactic treatment plans for non-small cell lung cancer and determine the dose delivered to the PTV and OARs. MATERIALS AND METHODS: For 26 patients with stage-I NSCLC treatment plans were optimized with unit density (UD), an...
Autores principales: | Schuring, Danny, Hurkmans, Coen W |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515326/ https://www.ncbi.nlm.nih.gov/pubmed/18662379 http://dx.doi.org/10.1186/1748-717X-3-21 |
Ejemplares similares
-
Neuropathic pain; what we know and what we should do about it
por: Smith, Peter A.
Publicado: (2023) -
Commentary: What we should know about our learners
por: Groth, Shawn S., et al.
Publicado: (2020) -
Weight-based dosing in medication use: what should we know?
por: Pan, Sheng-dong, et al.
Publicado: (2016) -
What All We Should Know About Masks in COVID-19 Pandemic
por: Agrawal, Himanshu, et al.
Publicado: (2020) -
What We Know and What We Don't Know About Preventing Stroke
por: Burch, Druin
Publicado: (2014)